Understanding GLP-1 Receptor Agonists: How Semaglutide & Tirzepatide Work

If you've been paying attention to the weight-loss landscape over the past few years, you've likely heard the names semaglutide and tirzepatide — perhaps by their brand names Wegovy, Ozempic, Zepbound, or Mounjaro. These medications have fundamentally changed what's possible in medically supervised weight management. But what exactly are they, how do they work, and what can you realistically expect? Here's a clear breakdown.

What Are GLP-1 Receptor Agonists?

GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally produces in response to eating. Its job is to signal to the brain that you've had enough food, prompt the pancreas to release insulin, and slow down the rate at which your stomach empties. In people with obesity or metabolic dysfunction, this system often becomes blunted — the signals are weaker, the appetite drive wins, and the body holds onto excess weight.

GLP-1 receptor agonists are drugs designed to mimic and amplify this hormone. They bind to GLP-1 receptors throughout the body and activate the same pathways, but with a much longer duration of action than the natural hormone. The result is a sustained, powerful reduction in appetite combined with meaningful improvements in blood sugar regulation.

The Incretin Mechanism: Why This Approach Works

GLP-1 belongs to a class of hormones called incretins — gut-derived signals that communicate with the pancreas and brain after a meal. When GLP-1 receptors in the hypothalamus are activated, two important things happen: appetite-promoting neurons (neuropeptide Y and agouti-related protein) are suppressed, while satiety-promoting neurons (pro-opiomelanocortin) are activated. In plain language, your brain gets a strong, clear signal that you're full — and the relentless food noise that plagues many people trying to lose weight goes quiet.

In the gastrointestinal tract, GLP-1 receptor activation slows gastric emptying by inhibiting motor neurons in the gut wall. Food moves through the stomach more slowly, which extends the feeling of fullness after meals. In the pancreas, insulin secretion is enhanced in a glucose-dependent manner, meaning the pancreas releases more insulin when blood sugar is elevated but not when it's low — a significant safety advantage.

Semaglutide: The GLP-1 Selective Option

Semaglutide is a selective GLP-1 receptor agonist — it targets the GLP-1 pathway exclusively. Originally developed for type 2 diabetes (Ozempic), it was subsequently approved for chronic weight management at a higher dose (Wegovy, 2.4 mg weekly).

The clinical evidence is striking. Across the landmark STEP trials — the largest phase 3 weight-management studies of semaglutide — participants without type 2 diabetes lost an average of 14.9% to 17.4% of their body weight over 68 weeks with the 2.4 mg dose. Between 69% and 79% of participants achieved at least 10% weight loss, and 51% to 64% achieved at least 15% — results that were previously seen only with bariatric surgery. In the two-year STEP 5 trial, the average weight loss was 15.2%, compared to just 2.6% for placebo.

Tirzepatide: The Dual GLP-1/GIP Agonist

Tirzepatide raises the bar further. It's a dual agonist, targeting both the GLP-1 receptor and a second incretin receptor: GIP (glucose-dependent insulinotropic polypeptide). Scientists have termed it a "twincretin" because it harnesses two complementary pathways simultaneously.

GIP and GLP-1 receptors work synergistically. GIP enhances the insulin response, improves fat metabolism, and appears to amplify the weight-loss effect of GLP-1 signaling. Tirzepatide is designed as an imbalanced agonist — it has full potency at the GIP receptor and partial agonism at the GLP-1 receptor, a configuration that appears to maximize efficacy while maintaining tolerability.

The SURMOUNT-1 trial results confirmed tirzepatide's exceptional performance. Participants taking tirzepatide achieved average weight reductions of 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) over 72 weeks — compared to just 2.4% for placebo. At the highest dose, 63% of participants achieved at least 20% body weight reduction, and 39.7% lost at least 25%. Roughly nine out of ten participants on any dose of tirzepatide lost at least 5% of their body weight.

Semaglutide vs. Tirzepatide: How to Choose

Both medications are highly effective. The right choice depends on your health profile, insurance coverage, and tolerance.

Tirzepatide generally produces greater average weight loss, but semaglutide has a longer track record and may be better tolerated in some individuals.

Who Is a Good Candidate?

These medications are typically appropriate for adults who meet one of the following criteria:

• BMI of 30 or higher (obesity)
• BMI of 27 or higher with at least one weight-related condition, such as hypertension, type 2 diabetes, high cholesterol, or sleep apnea

They are not appropriate for individuals with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or during pregnancy. A thorough evaluation by a licensed provider — including a review of your health history, current medications, and goals — is the right starting point.

What to Expect During Treatment

Titration schedule: Neither medication is started at its therapeutic dose. Both use a gradual dose escalation to allow the body to adapt and reduce GI side effects.

For semaglutide (Wegovy), the standard titration is:

• Weeks 1–4: 0.25 mg weekly
• Weeks 5–8: 0.5 mg weekly
• Weeks 9–12: 1.0 mg weekly
• Weeks 13–16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maintenance)

For tirzepatide (Zepbound), dosing begins at 2.5 mg weekly and increases by 2.5 mg every four weeks, with a maximum dose of 15 mg weekly reached after approximately 20 weeks.

Common side effects are primarily gastrointestinal — nausea is the most frequently reported, occurring in roughly 20–40% of patients across different agents. Vomiting, diarrhea, constipation, and bloating are also common, particularly during dose escalation. These symptoms typically improve as the body adjusts. Eating smaller meals, avoiding high-fat foods, and staying well-hydrated can help manage them.

Timeline for results: Most people begin noticing appetite changes within the first two to four weeks. Visible weight loss often becomes apparent by weeks six to eight, with the most significant changes occurring after reaching and maintaining the full dose. The major clinical trials measured outcomes at 68–72 weeks, and the data consistently shows that results continue to improve throughout the treatment period.

It's also worth understanding that these medications work best as part of a comprehensive program that includes attention to nutrition and physical activity. They are powerful tools — not replacements for sustainable habits.

As with any prescription medication, individual results vary. A licensed Madison Meds provider can help determine whether GLP-1 therapy is right for you.